J. Goldman & Co’s Regenxbio RGNX Stock Holding History

J. Goldman & Co’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,000	Closed	-$1.66M	–	421
2017 Q4	$1.66M	Buy	+50,000	New	+$1.51M	0.09%	205

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

J. Goldman & Co's RGNX Position: Q1 2018 in Review

J. Goldman & Co sold out of Regenxbio (RGNX) in Q1 2018, closing a stake of 55,911 shares — an estimated $1.86M sold.

J. Goldman & Co first reported a position in RGNX in Q3 2017 and held it in 2 quarters. The position peaked at $2.47M in Q3 2017. 120 funds tracked by Wall St. Rank hold RGNX as of Q1 2018.

J. Goldman & Co reported no remaining Regenxbio position as of Q1 2018 after selling out during the quarter.
J. Goldman & Co sold 55,911 Regenxbio shares in Q1 2018, an estimated $1.86M.
J. Goldman & Co first reported a position in Regenxbio in Q3 2017 and held it in 2 quarters.
J. Goldman & Co's Regenxbio position peaked at $2.47M in Q3 2017.
120 funds tracked by Wall St. Rank held Regenxbio as of Q1 2018.

Based on J. Goldman & Co's 13F filing for Q1 2018, filed 15 May 2018.